(Q33401218)

English

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

Robert Stuart

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Parameswaran Hari

object named as

Parameswaran Hari

15

0 references

Hagop Kantarjian

23

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

19

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

object named as

David Rizzieri

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

object named as

Karen Seiter

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gary J Schiller

4

object named as

Gary Schiller

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

object named as

Meir Wetzler

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tibor Kovacsovics

12

object named as

Tibor Kovacsovics

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

20

object named as

Eunice S Wang

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

22

object named as

Dirk Huebner

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Madan Jagasia

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Siddhartha Ganguly

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David Avigan

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Craig

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert Collins

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Maris

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stuart Goldberg

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jochen Greiner

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Norbert Vey

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christian Recher

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Vasconcelles

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

14 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2492-2499

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

What is the role of reduced-intensity transplantation in the treatment of older patients with AML?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Treatment of relapsed acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Hematopoietic stem cell transplantation in adults with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Age and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Biochemical modulation of cytarabine triphosphate by clofarabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

Synthesis and biological activity of 2'-fluoro-2-halo derivatives of 9-.beta.-D-arabinofuranosyladenine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

21 June 2018

How I treat acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

31 October 2018

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

31 October 2018

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

31 October 2018

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

31 October 2018

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874149

31 October 2018

A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22585697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22585697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22585697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-cont

1 reference

https://pubmed.ncbi.nlm.nih.gov/22585697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.37.9743

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

release_zkjbsmz24zbyxnuxfny5x3jbse

1 reference

https://api.fatcat.wiki/v0/release/zkjbsmz24zbyxnuxfny5x3jbse

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33401218&oldid=1856484054"